Literature DB >> 9807329

Urokinase efficacy in the restoration of hemodialysis catheter function.

C Meers1, E B Toffelmire.   

Abstract

Thrombus formation is a common cause of hemodialysis catheter malfunction. When thrombus or fibrin sheath restrict the flow of blood through one or both lumens, the catheter may need to be replaced. A less invasive, potentially lower cost option may be the instillation of low dose urokinase to degrade fibrin and restore catheter function. This study examines the efficacy of urokinase in improving blood flow and maintaining catheter patency. In a one-year period, urokinase was utilized in 25 dual lumen hemodialysis catheters (20 temporary, five permanent) in 22 patients. Blood flow and arterial and venous pressures were monitored before and after instillation. Urokinase administration successfully restored function in 20 catheters (80%). Paired t-tests demonstrated a significant improvement in blood flow and arterial pressure (p < 0.01) following urokinase. Catheter patency was extended for a mean of 18.0 days (range 0-90 days). The cost effectiveness of urokinase was evaluated in terms of direct costs, such as the cost of urokinase or materials to replace catheters, and indirect costs such as nursing and physician time and delays in dialysis scheduling. The results of this study suggest that judicious use of urokinase is a cost-effective, non-invasive method of restoring blood flow and extending patency in hemodialysis catheters.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9807329

Source DB:  PubMed          Journal:  J CANNT        ISSN: 1483-698X


  3 in total

1.  Improvement of hemodialysis catheter function with tenecteplase: a phase III, open-label study: TROPICS 4.

Authors:  Steven Fishbane; Samuel L Milligan; Kenneth D Lempert; Joachim E W Hertel; James B Wetmore; Matthew J Oliver; Martha Blaney; Barbara S Gillespie; Joan R Jacobs; Susan M Begelman
Journal:  J Thromb Thrombolysis       Date:  2011-01       Impact factor: 2.300

2.  Fibrin sheaths in central venous port catheters: treatment with low-dose, single injection of urokinase on an outpatient basis.

Authors:  De-Hua Chang; Kamal Mammadov; Tilman Hickethier; Jan Borggrefe; Martin Hellmich; David Maintz; Christoph Kabbasch
Journal:  Ther Clin Risk Manag       Date:  2017-01-24       Impact factor: 2.423

3.  Stability of Recombinant Tissue Plasminogen Activator at -30 °C over One Year.

Authors:  Abdulmalik Alkatheri
Journal:  Pharmaceuticals (Basel)       Date:  2013-01-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.